查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1987163

失智症治疗药物的市场规模、份额、趋势和预测：按适应症、药物类别、分销管道和地区划分，2026-2034 年

Dementia Drugs Market Size, Share, Trends and Forecast by Indication, Drug Class, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

2025年全球失智症治疗市场规模为209.8亿美元。展望未来，IMARC集团预测，该市场将以6.6%的复合年增长率从2026年成长至2034年，到2034年达到373.7亿美元。目前，北美市场主导地位，预计2025年将占32%的市场。该地区拥有完善的医疗基础设施、较高的诊断意识、对药物研发的大量投入以及可靠的支付机制，这些因素促进了成熟疗法和创新治疗方法的应用，并推动了失智症治疗方法市场份额的增长。

全球人口快速老化，以及阿兹海默症和血管性失智症等神经退化性疾病盛行率的显着上升，是全球失智症治疗市场的主要驱动力。随着人们对早期诊断和及时介入的认识不断提高，越来越多的人寻求治疗，患者群体也不断扩大。此外，政府和机构对失智症研究投入的增加，正在加速创新疗法的发现，例如针对疾病潜在机製而非仅仅治疗症状的疾病缓解疾病药物。从单纯的症状治疗转向生物製药和单株抗体，正在改变治疗方式，并推动失智症治疗市场的成长。此外，已开发国家和开发中国家医疗保健支出的增加，以及神经系统疾病保险覆盖范围的扩大，使得患者更容易获得尖端的失智症治疗，进一步促进了全球市场的稳定成长。

美国之所以发展成为失智症治疗领域的庞大市场，原因有以下几点：其强大的研究基础设施、完善的医疗保健体係以及积极的法规环境，促进了尖端失智症疗法的快速商业化。政府致力于提高公众对失智症的认知，并资助专门的研究项目，这些倡议也为国内产业的发展提供了支持。例如，阿兹海默症协会估计，到2025年，美国将有720万65岁及以上的老年人患有阿兹海默症，这凸显了需要治疗性介入的庞大且不断增长的人群。神经影像学和基于生物标记的评估等先进诊断技术的普及，有助于早期发现和启动治疗。此外，联邦医疗保险（Medicare）和核准的失智症治疗保险体系确保了患者的广泛可及性，使美国在失智症治疗市场中占据了举足轻重的地位。

失智症治疗市场的发展趋势：

扩大疾病修正治疗的应用

随着缓解疾病疗法（即着眼于神经退化性疾病的潜在发病机製而非仅仅治疗症状的疗法）的日益普及，失智症治疗市场正经历着革命性的变革。旨在减少大脑中β-淀粉样蛋白斑块的抗淀粉样蛋白单株抗体，随着越来越多的临床数据支持其疗效，正受到神经科和医疗保健专业人员的青睐。这些前沿生物製药代表着与传统症状治疗的模式转移，因为它们有可能阻止认知衰退，并维持早期患者的功能独立性。例如，如果美国食品药物管理局(FDA) 在 2025 年 1 月核准LEQEMBI（lecanemab）静脉维持治疗的补充生技药品核准申请 (sBLA)，那么已完成第一阶段治疗的患者将能够转为每月一次的输注方案。不断扩充的抗Tau蛋白疗法和联合治疗研发管线进一步拓展了失智症治疗的选择。

全球人口老化正在推动需求成长。

神经系统疾病的盛行率老龄化增长而急剧上升，全球老化成为推动失智症治疗需求的主要因素。在已开发国家和开发中国家，预期寿命延长和出生率下降等人口结构变化导致人口老化，进而导致需要失智症治疗的患者人数增加。各国政府和医疗机构正在製定国家政策以应对日益严重的失智症问题。此外，人们对失智症的征兆和症状的认识不断提高，促使更多人寻求医疗协助，从而增加了接受失智症治疗的患者人数。新兴经济体医疗基础设施的改善扩大了神经系统疾病医疗服务的覆盖范围，进一步刺激了对失智症药物的需求。这种由人口结构变化驱动的需求促使医疗系统加强神经系统疾病的诊疗能力，并鼓励製药公司投资研发新的治疗方法，从而支持全球全部区域失智症治疗市场预计的持续成长。

数位诊断技术与个人化医疗的进步

先进的数位诊断技术与个人化医疗方法的结合，显着提升了失智症的早期检测和个人化治疗水准。基于生物标记的诊断方法，例如血液检测、脑脊髓液分析和淀粉样蛋白正子断层扫描（PET），能够帮助医生在疾病的早期阶段识别其发病机制，从而在治疗性介入最为有效的时候进行干预。这种早期诊断能力使得更多患者能够接受治疗，进而增加了对已通过核准的失智症药物的需求。此外，神经影像学结果和认知功能评估数据正被应用于人工智慧和机器学习演算法的分析，以支援更精准的临床决策，并为每位患者选择最合适的治疗方法。随着远端医疗平台和远距认知监测工具的普及，患者获得专业神经科护理的机会进一步增加，尤其是在贫困和农村地区。同时，製药公司正日益利用数位健康数据和真实世界数据（REW）来改进治疗通讯协定，并开发能够根据特定患者特征匹配最佳治疗方案的伴随诊断，从而推动失智症药物市场的扩张。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 二手资讯
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球失智症治疗市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依应用领域划分

  • 路易氏体失智症
  • 帕金森氏症和失智症
  • 阿兹海默症
  • 血管性失智症
  • 其他的

第七章 市场区隔：依药物类别划分

  • 胆碱酯酶抑制剂
  • NMDA拮抗剂及其组合药物

第八章 市场区隔：依分销通路划分

  • 零售药房
  • 医院药房
  • 网路药房

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章：促进因素、阻碍因素和机会

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Abbvie Inc.
    • Apotex Inc.
    • Biogen Inc.
    • Eisai Co. Ltd.
    • Johnson & Johnson
    • Merck & Co. Inc.
Product Code: SR112026A7490

The global dementia drugs market size was valued at USD 20.98 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 37.37 Billion by 2034, exhibiting a CAGR of 6.6% from 2026-2034. North America currently dominates the market, holding a market share of 32% in 2025. The region benefits from advanced healthcare infrastructure, high diagnostic awareness, large investments in pharmaceutical R&D, and reliable payment mechanisms that facilitate the widespread adoption of both established and novel dementia treatments, all contributing to the dementia drugs market share.

The world's rapidly aging population, which has resulted in a substantial increase in the prevalence of neurodegenerative disorders like Alzheimer's disease and vascular dementia, is the primary driver of the global market for dementia drugs. As more people seek therapy as a result of greater awareness of early diagnosis and timely action, the pool of addressable patients is expanding. Additionally, increased government and institutional funding for dementia research is accelerating the discovery of innovative therapeutic agents, such as disease-modifying drugs that target underlying disease mechanisms rather than just treating symptoms. The shift from purely symptomatic treatments toward biologic agents and monoclonal antibodies is reshaping the treatment landscape, supporting the dementia drugs market growth. Furthermore, rising healthcare spending in both developed and developing nations, along with increased insurance coverage for neurological disorders, is improving patient access to cutting-edge dementia treatments and encouraging steady global market growth.

The US has grown into a sizable market for dementia drugs for a number of reasons. The rapid commercialization of cutting-edge dementia medicines is facilitated by the country's strong research infrastructure, established healthcare system, and proactive regulatory environment. Government initiatives to increase dementia awareness and finance specialist research programs are also helping the home industry. The Alzheimer's Association, for example, estimates that 7.2 million Americans 65 and older will have Alzheimer's disease in 2025, highlighting the sizeable and expanding patient population in need of therapeutic intervention. Early detection and treatment initiation are supported by the availability of sophisticated diagnostic techniques, such as neuroimaging technology and biomarker-based evaluations. Furthermore, Medicare coverage for authorized dementia treatments and strong insurance frameworks guarantee widespread patient access, positioning the United States as a key contributor to the dementia drugs market outlook.

DEMENTIA DRUGS MARKET TRENDS:

Rising Adoption of Disease-Modifying Therapies

With the growing use of disease-modifying treatments that focus on the underlying pathogenic mechanisms of neurodegenerative disorders rather than just treating their symptoms, the market for dementia medications is undergoing a revolutionary change. With more and more clinical data proving its effectiveness, anti-amyloid monoclonal antibodies, which are intended to lessen amyloid-beta plaques in the brain, are becoming increasingly popular among neurologists and medical professionals. These cutting-edge biologics provide the potential to arrest cognitive decline and maintain functional independence in individuals with early-stage illness, marking a paradigm shift from traditional symptomatic therapies. For example, patients who finished the first phase of treatment could switch to a once-monthly infusion schedule once the U.S. FDA approved the Supplemental Biologics License Application (sBLA) for LEQEMBI (lecanemab) intravenous maintenance dosage in January 2025. The growing pipeline of anti-tau and combination therapies further reinforces the expanding therapeutic arsenal available for dementia management.

Expanding Global Aging Population Driving Demand

Given that the prevalence of neurological illnesses rises sharply with age, the world's aging population is also a major factor driving up demand for dementia treatments. In both industrialized and developing nations, the population is aging due to demographic shifts like as longer life expectancies and lower birth rates, which increases the need for dementia treatment patients. In order to address the growing prevalence of dementia, governments and healthcare organizations are also developing national policies. Additionally, as more people become aware of the signs and symptoms of dementia, more people are consulting with doctors, which expands the number of people receiving dementia therapy. The demand for dementia drugs is being supported by the expansion of access to neurological healthcare services brought about by the development of healthcare infrastructure in emerging nations. This demographic-driven demand is pushing healthcare systems to improve their neurological care capacities and pharmaceutical companies to invest in the development of new treatments, supporting sustained dementia drugs market forecast expansion across all major regions globally.

Advancing Digital Diagnostics and Personalized Treatment

The combination of advanced digital diagnostic technologies and customized medicine approaches is significantly improving the early identification and individualized treatment of dementia. Biomarker-based diagnostic methods, including as blood-based assays, cerebrospinal fluid analysis, and amyloid positron emission tomography scans, are assisting doctors in identifying disease pathology early on, when therapeutic interventions are most effective. Because of these earlier diagnostic capabilities, more people are able to receive treatment, which in turn is driving up demand for approved dementia medications. Additionally, neuroimaging results and cognitive assessment data are being evaluated using artificial intelligence and machine learning algorithms to support more precise clinical decision-making and the optimal therapy option for each patient. Access to specialized neurology consultations is being further improved by the expanding use of telemedicine platforms and remote cognitive monitoring tools, especially for patients in impoverished and rural locations. Additionally, pharmaceutical firms are using digital health data and real-world evidence more and more to improve treatment protocols and create companion diagnostics that match particular patient profiles with the best treatment plans, thereby contributing to the expanding dementia drugs market trends.

DEMENTIA DRUGS INDUSTRY SEGMENTATION:

Analysis by Indication:

  • Lewy Body Dementia
  • Parkinson's Disease Dementia
  • Alzheimer's Disease
  • Vascular Dementia
  • Others

Alzheimer's disease holds 48% of the market share. Alzheimer's disease, recognized as the most prevalent form of dementia globally, represents the primary therapeutic focus within the dementia drugs landscape. The condition is characterized by progressive cognitive decline, memory impairment, and loss of functional independence, necessitating long-term pharmacological management. The dominant position of this segment is attributed to the high prevalence of Alzheimer's among elderly populations, strong clinical awareness, and the availability of multiple approved treatment options including cholinesterase inhibitors and NMDA receptor antagonists. For example, the World Health Organization reports that between 60 and 70 percent of dementia cases worldwide are caused by Alzheimer's disease, demonstrating the disease's extreme frequency among neurodegenerative diseases. Furthermore, the recent approval and commercialization of disease-modifying anti-amyloid therapies specifically targeting Alzheimer's pathology are generating substantial new revenue streams and reinforcing the segment's leading market position.

Analysis by Drug Class:

  • Cholinesterase Inhibitors
  • NMDA Antagonists and its Combination Drugs

Cholinesterase inhibitors lead the market with a share of 45%. Cholinesterase inhibitors are the most widely used class of drugs in the dementia drugs market, acting through the inhibition of acetylcholine breakdown by preventing the action of acetylcholinesterase, an enzyme responsible for the degradation of acetylcholine, a neurotransmitter that plays a pivotal role in memory and cognitive functions. The widespread use of cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, in the treatment of mild to moderate dementia has made this class of drugs the gold standard in dementia pharmacotherapy. The widespread use of these drugs in generic forms ensures widespread accessibility and affordability, further enhancing market penetration in both developed and developing countries. Moreover, the adaptability of these drugs in the treatment of various forms of dementia, including Alzheimer's disease and Lewy body dementia, has further contributed to the sustained use of these drugs. Ongoing research continues to validate the long-term cognitive and functional benefits associated with cholinesterase inhibitor therapy, further enhancing physician confidence in the use of these drugs as first-line pharmacologic agents. Moreover, the development of novel drug delivery systems, including transdermal patches and extended-release oral preparations, is further enhancing patient compliance and utilization.

Analysis by Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Retail pharmacies dominate the market, with a share of 50%. Retail pharmacies are the main distribution channel for dementia medications, providing patients with convenient access to chronic disease management therapies via community-based retail pharmacy outlets. The pre-eminence of this sector is a result of the chronic nature of dementia therapy, which necessitates ongoing prescription refills that are best managed via accessible retail pharmacy networks. Most dementia medications, especially oral cholinesterase inhibitors and NMDA receptor antagonists, are prescribed as ongoing outpatient therapies, making retail pharmacies the logical point of access for patients and families. In addition, the development of pharmacy benefit management programs and insurance coverage structures continues to facilitate the use of retail pharmacies for the dispensing of dementia medications. The increasing alignment of pharmacist-provided medication management services, such as medication adherence and therapeutic monitoring, is further enhancing the role of retail pharmacies in dementia care. Moreover, the development of chain pharmacy networks and their strategic location ensures widespread availability of critical dementia medications.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America, accounting for 32% of the share, enjoys the leading position in the market. The dominance of this region is largely fueled by its well-developed healthcare infrastructure, large number of Alzheimer's and dementia patients in the aging population, and a progressive regulatory framework that encourages the swift approval and launch of promising new dementia treatments. The United States, being the largest country market in this region, is aided by significant government investments in neurological research, robust insurance coverage structures, and widespread acceptance of both traditional and new treatment modalities. Moreover, the presence of proactive national dementia plans, sophisticated diagnostic facilities, and successful pharmaceutical companies further cements the leading market status of North America. The growing accessibility of biomarker screening facilities and memory care centers is helping to promote earlier diagnosis and treatment in the region. In addition, public-private partnerships between academic medical institutions and pharmaceutical firms are helping to accelerate clinical trials and facilitate the swift translation of research advances into new commercialized treatment modalities.

KEY REGIONAL TAKEAWAYS:

United States Dementia Drugs Market Analysis

Due to its huge healthcare system, high illness prevalence, and strong pharmaceutical innovation ecosystem, the United States is the world's largest national market for dementia medications. The aged population is now significantly more vulnerable to Alzheimer's disease and other dementias due to the aging baby boomer generation, which has resulted in a persistent need for both symptomatic and disease-modifying treatments. Dementia research continues to get substantial support from federal organizations, such as the National Institutes of Health and the National Institute on Aging, which makes it easier to create and test new treatment options. Promising dementia therapies can enter the market more quickly thanks to the regulatory structure run by the U.S. Food and Drug Administration, which includes accelerated approval and breakthrough therapy designation procedures. Expanding Medicare and commercial insurance coverage guarantees widespread patient access to approved drugs, and growing use of biomarker-based diagnostic techniques is facilitating earlier disease identification and treatment commencement. Comprehensive patient evaluation and customized treatment planning are supported by the nation's extensive network of world-class academic medical centers and specialized memory care clinics. Furthermore, increasing public health initiatives aimed at raising awareness of dementia are promoting prompt medical consultations among vulnerable groups, which increases the number of patients who may be served and sustains the need for pharmaceuticals.

Europe Dementia Drugs Market Analysis

Due to its advanced healthcare systems, aging population, and increasing focus on managing neurological diseases throughout its main countries, Europe is a prominent market for dementia medications. The frequency of dementia is rising in countries like Germany, the UK, France, Italy, and Spain as a result of longer life expectancies and growing numbers of senior people. The region's national health systems are gradually increasing their coverage of dementia diagnosis and treatment, giving patients better access to both tried-and-true and cutting-edge treatment options. In order to guarantee that patients receive the most recent pharmacological developments, the European Medicines Agency's regulatory framework makes it easier for member states to evaluate and approve novel treatments. The development of next-generation dementia medicines and diagnostic tools is also being accelerated by cooperative research projects supported by European Union programs, which is bolstering the therapeutic landscape in the area. The region's increasing investment in multidisciplinary neurology centers and specialist dementia care facilities is improving patient care and promoting more all-encompassing treatment strategies. Additionally, the clinical understanding of neurodegenerative diseases is being advanced and knowledge exchanged by European research institutions through increased cross-border cooperation.

Asia-Pacific Dementia Drugs Market Analysis

Due to increasingly aging populations, rising disease prevalence, and improving healthcare infrastructure throughout major nations, the Asia-Pacific area is becoming one of the fastest-growing markets for dementia medications. The burden of neurodegenerative diseases is rising as a result of major population shifts in nations like China, Japan, India, South Korea, and Australia. To combat this escalating issue, governments throughout the area are boosting healthcare spending and putting national dementia programs into action. For instance, according to Eisai, approximately 17 million people in China were living with mild cognitive impairment or mild dementia caused by Alzheimer's disease in 2024, a number expected to rise substantially as the population ages. The Asia-Pacific area is positioned for continued market expansion due to the increasing availability of both patented and generic dementia medications, as well as enhanced diagnostic capabilities and increased clinical trial activity.

Latin America Dementia Drugs Market Analysis

Due to regional improvements in healthcare access, aging populations, and increased awareness of neurodegenerative disorders, the market for dementia drugs is progressively expanding in Latin America. In countries like Brazil and Mexico, where the population is getting older, dementia is becoming more common and treatment approaches are becoming more necessary. International pharmaceutical companies are expanding their market presence in the region to address the growing unmet therapeutic demands, and government healthcare systems are progressively including neurological care into their offerings. Additionally, growing healthcare literacy and urbanization are facilitating greater patient engagement with formal medical systems, leading to faster dementia diagnosis and treatment for a variety of socioeconomic groups.

Middle East and Africa Dementia Drugs Market Analysis

The market for dementia medications is progressively expanding in the Middle East and Africa due to factors such growing senior populations in major economies, better healthcare infrastructure, and growing awareness of neurodegenerative diseases. Although the area now has a comparatively lesser portion of the worldwide market, urbanization and demographic shifts are driving up the prevalence of dementia and increasing the demand for therapeutic solutions. The region's market is anticipated to rise as a result of healthcare modernization programs, rising pharmaceutical distribution networks, and increased government focus on managing chronic diseases. Furthermore, knowledge transfer and local capacity for dementia diagnosis and treatment delivery are being strengthened by growing collaborations between international organizations and regional healthcare authorities.

COMPETITIVE LANDSCAPE:

The coexistence of established pharmaceutical corporations and biotechnology companies with a focus on distinct techniques represents the competitive landscape in the dementia drug market. Leading businesses are actively working on research and development projects to improve their neurology products, with a focus on disease-modifying treatments that target the tau and amyloid-beta proteins. New chemicals are being developed more quickly because to partnerships between pharmaceutical corporations and academic institutions. Prominent businesses are developing biologics internally and partnering with others to commercialize them. To make therapy more convenient for patients, companies are also developing new medication delivery methods, such as transdermal and subcutaneous patches, and combination medicines. By creating more reasonably priced copies of the current cholinesterase inhibitors and NMDA receptor antagonists, generic businesses are also helping to open up the market. Furthermore, businesses are utilizing companion diagnostics and precision medicine's capabilities more and more to differentiate their goods and enhance their market standing in the competitive dementia treatment industry.

The report provides a comprehensive analysis of the competitive landscape in the dementia drugs market with detailed profiles of all major companies, including:

  • Abbvie Inc.
  • Apotex Inc.
  • Biogen Inc.
  • Eisai Co. Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the dementia drugs market?

2. What is the future outlook of dementia drugs market?

3. What are the key factors driving the dementia drugs market?

4. Which region accounts for the largest dementia drugs market share?

5. Which are the leading companies in the global dementia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Dementia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Lewy Body Dementia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Parkinson's Disease Dementia
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alzheimer's Disease
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Vascular Dementia
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cholinesterase Inhibitors
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 NMDA Antagonists and its Combination Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Retail Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospital Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Apotex Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Biogen Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Johnson & Johnson
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Dementia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Dementia Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Dementia Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Dementia Drugs Market: Breakup by Indication (in %), 2025
  • Figure 5: Global: Dementia Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 6: Global: Dementia Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Dementia Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Dementia Drugs (Lewy Body Dementia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Dementia Drugs (Lewy Body Dementia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Dementia Drugs (Parkinson's Disease Dementia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Dementia Drugs (Parkinson's Disease Dementia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Dementia Drugs (Alzheimer's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Dementia Drugs (Alzheimer's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Dementia Drugs (Vascular Dementia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Dementia Drugs (Vascular Dementia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Dementia Drugs (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Dementia Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Dementia Drugs (Cholinesterase Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Dementia Drugs (Cholinesterase Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Dementia Drugs (NMDA Antagonists and its Combination Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Dementia Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Dementia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Dementia Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Dementia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Dementia Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Dementia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Dementia Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Dementia Drugs Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Dementia Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Dementia Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Dementia Drugs Industry: Value Chain Analysis
  • Figure 79: Global: Dementia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Dementia Drugs Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Dementia Drugs Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 3: Global: Dementia Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 4: Global: Dementia Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Dementia Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Dementia Drugs Market: Competitive Structure
  • Table 7: Global: Dementia Drugs Market: Key Players